Interní Med. 2001; 3(10): 473-476

Nová léková forma fenofibrátu - Lipanthyl SUPRA

MUDr. Tomáš Doležal
Ústav farmakologie 3. LF UK, Praha

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležal T. Nová léková forma fenofibrátu - Lipanthyl SUPRA. Interní Med. 2001;3(10):473-476.

Fibráty patří mezi léky volby ve farmakoterapii hyperlipoproteinémií. Základní zástupce fibrátů, fenofibrát, byl poprvé registrován v roce 1975. Z důvodu nízké biologické dostupnosti (30 %) byla v 80. letech vyvinuta mikronizovaná léková forma. Díky redukci velikosti částic došlo ke zvýšení biologické dostupnosti asi o 30 %. Nyní se objevila další inovace lékové formy (Lipanthyl Supra) a biologická dostupnost vzrostla o dalších 25 %, čímž poklesla interindividuální variabilita v plazmatických koncentracích léčiva a snížil se vliv obsahu stravy na vstřebávání fenofibrátu. Dnes již také známe přesný mechanizmus účinku fibrátů, kterým je ovlivnění receptorů PPAR-a (peroxisome proliferator-activated receptors) v jádrech buněk. Fibráty prokázaly komplexní účinnost ve snižování hladin lipidů, v poslední době však roste jejich význam ve zvyšování hodnoty HDL-cholesterolu, jehož nízké hladiny jsou vedle hodnoty LDL-cholesterolu a triacylgycerolů nezávislým rizikových faktorem kardiovaskulárních chorob.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Castelli, W. P., Garrison, R. J., Wilson, P. W., Abbott, R. D., Kalousdian, S., and Kannel, W. B. (1986): Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838. Go to original source... Go to PubMed...
    2. Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Jr., Bangdiwala, S., and Tyroler, H. A. (1989): Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15. Go to original source... Go to PubMed...
    3. Guay, D. R. (1999): Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 33: 1083-1103. Go to original source... Go to PubMed...
    4. Guichard, J. P., Blouquin, P., and Qing, Y. (2000): A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin 16: 134-138. Go to original source...
    5. Kirchgassler, K. U., Schiffner-Rohe, J., and Stahlheber, U. (1997): Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia. Pharmacoeconomics 12: 237-246. Go to original source... Go to PubMed...
    6. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
    7. Rubins, H. B., Robins, S. J., Collins, D., Iranmanesh, A., Wilt, T. J., Mann, D., Mayo-Smith, M., Faas, F. H., Elam, M. B., Rutan, G. H., (1995): Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 75: 1196-1201. Go to original source... Go to PubMed...
    8. Sacco, R. L. and Boden-Albala, B. (2001): High-Density Lipoprotein Cholesterol and Risk of Stroke. JAMA 286: 1573-1574. Go to original source... Go to PubMed...
    9. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J. C., Najib, J., Maclouf, J., and Tedgui, A. (1998): Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793. Go to original source... Go to PubMed...
    10. Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., and Hennekens, C. H. (1991): A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325: 373-381. Go to original source... Go to PubMed...
    11. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J. C., Staels, B., and Auwerx, J. (1995): Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96: 741-750. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.